

# 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

NCT06395402

---

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Iowa
Enrollment	120 participants

## Key Eligibility Criteria

---

### Inclusion (14)

- In order to be eligible to participate in this study, an individual must meet all of the following criteria. A physical, with vital signs, concomitant medication review, and medical history must be completed within 60 calendar days to confirm appropriateness of Lutathera treatment as well as to foundation for listed criteria.
- Provision of signed and dated informed consent form.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Aged e 18 years at time of consent.
- Pathologically confirmed (histology or cytology) malignant neoplasm that is determined to be a well-differentiated neuroendocrine tumor (Ki-67 d 20%) with the primary tumor location known or believed to be gastroenteropancreatic origin (GEP-NET) ... and 9 more (see full listing online)

### Exclusion (9)

- Individuals who are pregnant or lactating (note: potential participants should not engage in 'pump \& dump' strategy; lactation must be discontinued).
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (requiring inpatient admission or a delay to start of therapy), fever, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Surgery, radiation therapy, or chemotherapy d 4 weeks of C1D1 (Toxicities from prior therapies should have resolved to d CTCAE grade 1 or a new baseline established).
- Prior peptide-receptor radiotherapy (PRRT).
- Therapeutic investigational drug within 4 weeks of C1D1 (imaging agents are acceptable). ... and 4 more (see full listing online)

## Locations (1 total)

---

Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, Iowa, United States

---

<https://clinicaltrials.gov/study/NCT06395402>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).